Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734852 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31358862 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL15986104 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL31711351 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL13855547 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL17392871 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL1243678 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL358468 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL308741 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL20162089 | 1.00 | NOD1 (0.74) | NOD1CASP2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0615522-B1 | MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK | PEPTECH UK LTD (GB) | 1999-09-22 | — | — | EP | claimed |
| WO-1998009989-A1 | THE USE OF MURAMYLPEPTIDES IN THE TREATMENT OF MYELOSUPPRESSED OR OTHERWISE IMMUNOCOMPROMISED STATES | PEPTECH (UK) LIMITED (GB) | 1998-03-12 | — | — | WO | claimed |
| CN-1162920-A | Use of muramyl peptide compounds | PEPTECH UK LTD (GB) | 1997-10-22 | — | — | CN | claimed |
| EP-0782454-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH (UK) (GB) | 1997-07-09 | — | — | EP | claimed |
| EP-0768888-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH (UK) LIMITED (GB) | 1997-04-23 | — | — | EP | claimed |
| EP-0722332-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1996009063-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH(UK) LIMITED (GB) | 1996-03-28 | — | — | WO | claimed |
| WO-1996001645-A1 | USE OF MURAMYL PEPTIDE COMPOUNDS | PEPTECH(UK) LIMITED (GB) | 1996-01-25 | — | — | WO | claimed |
| EP-0689449-A1 | THERAPEUTICAL COMPOSITIONS FOR USE IN HUMANS, CHARACTERISED BY A COMBINATION OF A MURAMYL PEPTIDE AND A CYTOKINE | VACSYN S.A. (FR) | 1996-01-03 | — | — | EP | claimed |
| WO-1995010293-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1995-04-20 | — | — | WO | claimed |
| WO-1994021275-A1 | THERAPEUTICAL COMPOSITIONS FOR USE IN HUMANS, CHARACTERISED BY A COMBINATION OF A MURAMYL PEPTIDE AND A CYTOKINE | VACSYN S.A. (FR) | 1994-09-29 | — | — | WO | claimed |
| WO-1993010148-A1 | MURAMYL COMPOUNDS FOR TREATMENT OF SEPTIC SHOCK | PEPTECH (UK) LIMITED (GB) | 1993-05-27 | — | — | WO | claimed |
| EP-0021367-B1 | MURAMYLDIPEPTIDE DERIVATIVES, PROCESS FOR PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-04-06 | — | — | EP | claimed |
| EP-0021367-A1 | Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1981-01-07 | — | — | EP | claimed |
| JP-63093724-A | — | — | None | — | — | JP | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-0139481-A2 | Surface modification using N-acyl lysines | AJINOMOTO CO., INC. (JP) | 1985-05-02 | — | — | EP | disclosed |
| EP-0021367-B1 | MURAMYLDIPEPTIDE DERIVATIVES, PROCESS FOR PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-04-06 | — | — | EP | disclosed |
| EP-0021367-A1 | Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | NOD1 4241/4885CASP2 4449/4885GNAI3 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.